CA3069295A1 - Traitement de saignements gastro-intestinaux chez des patients atteints d'une forme grave de la maladie de von willebrand par l'administration de vwf recombine - Google Patents

Traitement de saignements gastro-intestinaux chez des patients atteints d'une forme grave de la maladie de von willebrand par l'administration de vwf recombine Download PDF

Info

Publication number
CA3069295A1
CA3069295A1 CA3069295A CA3069295A CA3069295A1 CA 3069295 A1 CA3069295 A1 CA 3069295A1 CA 3069295 A CA3069295 A CA 3069295A CA 3069295 A CA3069295 A CA 3069295A CA 3069295 A1 CA3069295 A1 CA 3069295A1
Authority
CA
Canada
Prior art keywords
var
rvwf
vwf
infusion
von willebrand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069295A
Other languages
English (en)
Inventor
Miranda CHAPMAN
Bruce EWENSTEIN
Bettina PLODER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of CA3069295A1 publication Critical patent/CA3069295A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode de traitement de saignements gastro-intestinaux chez un sujet atteint d'une forme grave de la maladie de von Willebrand comprenant l'administration au sujet d'au moins une dose du facteur de von Willebrand recombiné (rVWF) située dans la plage allant d'environ 40 UI/kg à environ 100 UI/kg, la première dose comprenant en outre le facteur VIII recombiné (rFVIII).
CA3069295A 2017-07-07 2018-07-09 Traitement de saignements gastro-intestinaux chez des patients atteints d'une forme grave de la maladie de von willebrand par l'administration de vwf recombine Pending CA3069295A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07
US62/530,027 2017-07-07
PCT/US2018/041320 WO2019010497A1 (fr) 2017-07-07 2018-07-09 Traitement de saignements gastro-intestinaux chez des patients atteints d'une forme grave de la maladie de von willebrand par l'administration de vwf recombiné

Publications (1)

Publication Number Publication Date
CA3069295A1 true CA3069295A1 (fr) 2019-01-10

Family

ID=63036433

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069295A Pending CA3069295A1 (fr) 2017-07-07 2018-07-09 Traitement de saignements gastro-intestinaux chez des patients atteints d'une forme grave de la maladie de von willebrand par l'administration de vwf recombine

Country Status (10)

Country Link
US (4) US10632176B2 (fr)
EP (1) EP3648788B1 (fr)
JP (2) JP7307047B2 (fr)
KR (1) KR20200037235A (fr)
CN (1) CN111436193A (fr)
AU (1) AU2018298233A1 (fr)
BR (1) BR112020000321A2 (fr)
CA (1) CA3069295A1 (fr)
CO (1) CO2020001322A2 (fr)
WO (1) WO2019010497A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (fr) 2003-07-31 2005-02-10 Zlb Behring Gmbh Procede d'extension de la demi-vie du facteur viii
EP1593388A1 (fr) 2004-05-05 2005-11-09 ZLB Behring GmbH Protéines plasmatiques concentrées à usage thérapeutique comprenant du facteur de von willebrand sous forme de multimères de poids moleculaire élevé
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006071801A2 (fr) 2004-12-27 2006-07-06 Baxter International Inc Conjugues entre polymeres et facteurs von willbrand
PL3121266T3 (pl) 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
WO2008151817A1 (fr) 2007-06-13 2008-12-18 Csl Behring Gmbh Utilisation de préparations stabilisées du vwf avec du fviii et de préparations du vwf sans fviii destinées à une administration extra-vasculaire dans la thérapie et le traitement prophylactique de troubles de saignements
EP2222329A1 (fr) 2007-11-09 2010-09-01 Baxter International Inc. Facteur viii et facteur de von willebrand recombinés modifiés et procédé d'utilisation
JP5784907B2 (ja) 2007-12-28 2015-09-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 組換え型ｖｗｆ製剤
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
CN103919736A (zh) 2008-10-21 2014-07-16 巴克斯特国际公司 冻干的重组vwf配方
AU2010279463A1 (en) 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
CN107286235A (zh) 2010-07-08 2017-10-24 百深有限责任公司 在细胞培养物中生产重组高分子量 vWF 的方法
RU2628537C2 (ru) 2011-06-10 2017-08-18 Баксалта Инкорпорейтед Лечение нарушений свертываемости крови путем введения рекомбинантного фв
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF

Also Published As

Publication number Publication date
BR112020000321A2 (pt) 2020-07-14
AU2018298233A1 (en) 2020-01-30
US11529395B2 (en) 2022-12-20
WO2019010497A1 (fr) 2019-01-10
RU2020105682A (ru) 2021-08-10
US20230122958A1 (en) 2023-04-20
CO2020001322A2 (es) 2020-02-18
KR20200037235A (ko) 2020-04-08
JP7307047B2 (ja) 2023-07-11
EP3648788B1 (fr) 2024-05-22
CN111436193A (zh) 2020-07-21
US10632176B2 (en) 2020-04-28
JP2023123738A (ja) 2023-09-05
US20200206318A1 (en) 2020-07-02
EP3648788A1 (fr) 2020-05-13
US20210169989A1 (en) 2021-06-10
US10905746B2 (en) 2021-02-02
JP2020526525A (ja) 2020-08-31
RU2020105682A3 (fr) 2021-10-15
US20190091299A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
US11191813B2 (en) Lyophilized recombinant VWF formulations
AU2017206235B2 (en) Treatment of Coagulation Disease by Administration of Recombinant VWF
US20230122958A1 (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
US20240009279A1 (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
US20220395560A1 (en) METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
US20200261546A1 (en) METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
US20230398188A1 (en) Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
RU2774720C2 (ru) ЛЕЧЕНИЕ ЖЕЛУДОЧНО-КИШЕЧНОГО КРОВОТЕЧЕНИЯ У ПАЦИЕНТОВ С ТЯЖЕЛОЙ ФОРМОЙ БОЛЕЗНИ ФОН ВИЛЛЕБРАНДА ПУТЕМ ВВЕДЕНИЯ РЕКОМБИНАНТНОГО ФфВ
EP4028046B1 (fr) Méthodes de traitement liés à des complexes du facteur de von willebrand et du complément c1q

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221002

EEER Examination request

Effective date: 20221002

EEER Examination request

Effective date: 20221002